Suzuki A - Search Results

1

CYP2C19 polymorphism affects personality traits of Japanese females.

Ishii G, Suzuki A, Oshino S, Shiraishi H, Otani K. Ishii G, et al. Among authors: suzuki a. Neurosci Lett. 2007 Jan 3;411(1):77-80. doi: 10.1016/j.neulet.2006.10.012. Epub 2006 Oct 18. Neurosci Lett. 2007. PMID: 17052843

2

Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.

Yasui-Furukori N, Kondo T, Ishida M, Furukori H, Suzuki A, Kaneko S, Inoue M, Otani K. Yasui-Furukori N, et al. Among authors: suzuki a. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):53-7. doi: 10.1016/s0278-5846(01)00218-4. Prog Neuropsychopharmacol Biol Psychiatry. 2002. PMID: 11853119 Clinical Trial.

3

Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.

Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S, Otani K. Yasui-Furukori N, et al. Among authors: suzuki a. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):575-8. doi: 10.1016/s0278-5846(01)00310-4. Prog Neuropsychopharmacol Biol Psychiatry. 2002. PMID: 11999910

4

Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome.

Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, Koshiro K, Otani K, Kaneko S. Mihara K, et al. Among authors: suzuki a. Am J Med Genet B Neuropsychiatr Genet. 2003 Feb;117B(1):57-60. doi: 10.1002/ajmg.b.10025. Am J Med Genet B Neuropsychiatr Genet. 2003. PMID: 12555236

5

Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.

Suzuki A, Yasui-Furukori N, Mihara K, Kondo T, Furukori H, Inoue Y, Kaneko S, Otani K. Suzuki A, et al. Ther Drug Monit. 2003 Apr;25(2):192-6. doi: 10.1097/00007691-200304000-00008. Ther Drug Monit. 2003. PMID: 12657913 Clinical Trial.

6

Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug.

Kato K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Kanno M, Otani K. Kato K, et al. Among authors: suzuki a. Ther Drug Monit. 2003 Aug;25(4):473-7. doi: 10.1097/00007691-200308000-00010. Ther Drug Monit. 2003. PMID: 12883232 Clinical Trial.

7

Interaction study between fluvoxamine and quazepam.

Kanda H, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Otani K. Kanda H, et al. Among authors: suzuki a. J Clin Pharmacol. 2003 Dec;43(12):1392-7. doi: 10.1177/0091270003258667. J Clin Pharmacol. 2003. PMID: 14615476 Clinical Trial.

8

Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity.

Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Tateishi T, Otani K. Fukasawa T, et al. Among authors: suzuki a. Ther Drug Monit. 2004 Oct;26(5):529-33. doi: 10.1097/00007691-200410000-00011. Ther Drug Monit. 2004. PMID: 15385836 Clinical Trial.

9

A three-factor model of the MADRS in major depressive disorder.

Suzuki A, Aoshima T, Fukasawa T, Yoshida K, Higuchi H, Shimizu T, Otani K. Suzuki A, et al. Depress Anxiety. 2005;21(2):95-7. doi: 10.1002/da.20058. Depress Anxiety. 2005. PMID: 15884092

10

Interaction study between enoxacin and fluvoxamine.

Kunii T, Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Tateishi T, Inoue Y, Otani K. Kunii T, et al. Among authors: suzuki a. Ther Drug Monit. 2005 Jun;27(3):349-53. doi: 10.1097/01.ftd.0000159134.94981.3f. Ther Drug Monit. 2005. PMID: 15905806 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,537 results

Search Page